Premium
Differential Receptor for Advanced Glycation End Products Expression in Preeclamptic, Intrauterine Growth Restricted, and Gestational Diabetic Placentas
Author(s) -
Alexander Kristen L.,
Mejia Camilo A.,
Jordan Clinton,
Nelson Michael B.,
Howell Brian M.,
Jones Cameron M.,
Reynolds Paul R.,
Arroyo Juan A.
Publication year - 2016
Publication title -
american journal of reproductive immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.071
H-Index - 97
eISSN - 1600-0897
pISSN - 1046-7408
DOI - 10.1111/aji.12462
Subject(s) - glycation , placenta , receptor , advanced glycation end product , medicine , gestational diabetes , preeclampsia , endocrinology , gestation , pregnancy , andrology , chemistry , biology , fetus , genetics
Problem Receptor for advanced glycation end products (RAGE) is a receptor implicated in the modulation of inflammation. Inflammation has been associated with pregnancy pathologies including preeclampsia (PE), intrauterine growth restriction (IUGR), and gestational diabetes mellitus (GDM). Our objective was to examine placental RAGE expression in PE, IUGR, and GDM complications. Method of study Human placental tissues were obtained for RAGE determination using Q‐PCR, immunohistochemistry, and Western blot. Invasive trophoblast cells were cultured and treated with AGES for RAGE activation studies. Results Compared to control placenta, we observed: (i) decreased RAGE gene expression during GDM, (ii) increased RAGE protein in the PE placenta, and (iii) decreased RAGE protein in the IUGR placenta. In trophoblast cells exposed AGEs, we observed: (i) decreased trophoblast invasion, (ii) increased c‐Jun N‐terminal kinases (JNK) and Extracellular signal‐regulated kinases (ERK), and (iii) increased TNF‐α and IL‐1β secretion. Conclusion We conclude that placental RAGE is activated during PE and that RAGE‐mediated inflammation in the trophoblast involves increased pro‐inflammatory cytokine secretion.